Boothbay Fund Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Boothbay Fund Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,154	Closed	-$1.53M	–	2508
2023 Q1	$1.47M	Buy	+16,154	New	+$948K	0.03%	821
2022 Q2	–	Sell	-8,564	Closed	-$255K	–	2810
2022 Q1	$281K	Buy	+8,564	New	+$254K	0.01%	1654
2021 Q1	–	Sell	-2,680	Closed	-$313K	–	1858
2020 Q4	$331K	Buy	+2,680	New	+$352K	0.01%	916

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's RETA Position: Q2 2023 in Review

Boothbay Fund Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 16,154 shares — an estimated $1.53M sold.

Boothbay Fund Management first reported a position in RETA in Q4 2020 and held it in 3 quarters. The position peaked at $1.47M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Boothbay Fund Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 16,154 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.53M.
Boothbay Fund Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 3 quarters.
Boothbay Fund Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.47M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.